ブース番号5N-16
カテゴリーアウトソーシング
Genovior Biotech Corporation
小間番号:5N-16
カテゴリー:アウトソーシング
Genovior is a dedicated CDMO focus on process development, scale up, formulation development, and productivity optimization under PIC/S GMP (cGMP, EU GMP) for our customers worldwide. Our one-stop services conveniently provide effective and efficient solution and our non-competition policy provides maximum security and protection in IP for our clients.
Genovior Biotech Corp. is a vertically integrated contract development and manufacture company, providing following services:
(a) process development of peptide or protein biologics from microbial or human recombinant fermentation processes
(b) formulation development of biological injectables
(c) manufacturing capacities of biologics, lyophilized injectable, and prefilled syringe/cartridge for preclinical, clinical, and commercial uses
Genovior Biotech Corp. is a vertically integrated contract development and manufacture company, providing following services:
(a) process development of peptide or protein biologics from microbial or human recombinant fermentation processes
(b) formulation development of biological injectables
(c) manufacturing capacities of biologics, lyophilized injectable, and prefilled syringe/cartridge for preclinical, clinical, and commercial uses
企業情報
住所 | 4F, 50-8, Keyan Road, Zhunan Township Taiwan 35053 35053 |
---|---|
URL | http:// |
contact@genovior.com.tw |
出展品目 |
Contract Manufacturing (CDMO/CMO) API Contract Manufacturing (CDMO/CMO) Injectables Pemetrexed Injection; 100mg & 500mg (Swissmedic & TFDA approved) Bortezomib Injection; 3.5mg (TFDA approved) Doxorubicin Injection; 10mg (TFDA approved) Docetaxel Injection; 20mg/mL (1mL/vial) (TFDA approved) Fulvestrant Injection; 250mg (TFDA approved) Gemcitabine Injection; 200mg (TFDA approved) Azacitidine Injection; 100mg (TFDA approved) Gemcitabine Injection; 200mg (TFDA approved) Ganciclovir Injection; 500mg (TFDA approved) Fulvestrant (API) Octreotide (API) Pemetrexed (API) Teriparatide (API) Azacitidine (API) Bortezomib (API) Semaglutide Injection (in development) Carfilzomib Injection (in development) Teriparatide Injection (in development) |
---|